Search results (203)
« Back to Publicationsssessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
Journal article
REITH C. et al, (2026), The Lancet
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
Journal article
Neuen BL. et al, (2026), JAMA, 335, 233 - 244
"Hi"s and "Lo"s of Targeting Serum Phosphate Levels in Hemodialysis.
Journal article
Mayne KJ. and Herrington WG., (2025), J Am Soc Nephrol, 36, 2328 - 2329
In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 mo.
Journal article
Turnbull I. et al, (2025), Ann Intern Med, 178
Polygenic prediction of coronary heart disease among 130,000 Mexican adults
Journal article
EMBERSON J. et al, (2025), European Journal of Preventive Cardiology (EJPC)
Effects Of Empagliflozin On Kidney And Cardiac Magnetic Resonance Imaging Measures In Patients With Chronic Kidney Disease: An EMPA-KIDNEY Mechanistic Substudy
Journal article
ZHU D. et al, (2025), American Journal of Kidney Diseases
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.
Journal article
Malijan GB. et al, (2025), Am J Kidney Dis
Effects of Sodium glucose co-transporter-2 inhibitors by diabetes status and level of albuminuria: a collaborative meta-analysis
Journal article
STAPLIN N. et al, (2025), Journal of the American Medical Association (JAMA)
Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.
Journal article
Turner M. et al, (2025), Hypertension (Dallas, Tex. : 1979)
Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings.
Journal article
Marx N. et al, (2025), Eur Heart J Qual Care Clin Outcomes, 11, 868 - 874
Glucose interference in urine biomarkers and implications for SGLT2 inhibition
Journal article
Malijan GB. et al, (2025), Kidney International Reports
Individual Participant Level Meta-Analysis Of The Effects Of Empagliflozin On Conventional And Exploratory Acute And Chronic Kidney Outcomes
Journal article
HERRINGTON W. et al, (2025), The Lancet Diabetes and Endocrinology
Individual Participant Level Meta-Analysis Of The Effects Of Empagliflozin On Conventional And Exploratory Acute And Chronic Kidney Outcomes
Journal article
HERRINGTON W. et al, (2025), The Lancet Diabetes and Endocrinology
Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.
Journal article
Oshima M. et al, (2025), Clin J Am Soc Nephrol, 20, 1206 - 1214